PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
- Conditions
- Diabetes Melliuts, Type 2
- Interventions
- Drug: 100 mg PF-05231023Drug: 150 mg PF-05231023Other: PlaceboDrug: 25 mg PF-05231023Drug: 50 mg PF-05231023
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT01673178
- Locations
- πΊπΈ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
πΊπΈProfil Institute for Clinical Research, Inc., Chula Vista, California, United States
πΊπΈDiablo Clinical Research, Inc., Walnut Creek, California, United States
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2012-08-23
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 403
- Registration Number
- NCT01671280
A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects
- Conditions
- Renal Disease
- Interventions
- Drug: 200 mg Ceftaroline fosamil
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01664065
- Locations
- π¬π§
Research Site, London, United Kingdom
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 396
- Registration Number
- NCT01664923
- Locations
- πΊπΈ
Alliance Urology Specialists, PA, Greensboro, North Carolina, United States
πΊπΈJohn Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
πΊπΈUCLA Clark Urology Clinic, Los Angeles, California, United States
Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01660334
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01658176
Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01655511
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT01654250
- Locations
- πΊπΈ
Westex Clinical Investigations, Lubbock, Texas, United States
πΊπΈLaboratory School, Huntington Beach, California, United States
πΊπΈClinical Study Centers, LLC, Little Rock, Arkansas, United States
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: AN2728 Topical Ointment, 2%
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT01652885
- Locations
- πΊπΈ
Anacor Investigational Site, Houston, Texas, United States
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
- Conditions
- Advanced Non-Hematologic Malignancies
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01653158
- Locations
- π¬π§
Pfizer Investigational Site, Sutton, Surrey, United Kingdom